RxDoctor Payments Data

Andin Mullis, MD

Clinical Cardiac Electrophysiology · Mobile, ALNPI 1871907022

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (46.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Boston Scientific at 38.7% of the total. Reporting peaked in 2022 at $17,106 and has fallen 59.1% since, to $6,989 in 2025.

$42,119in general payments, 2019–2025

Across 236 payments — averaging $178.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$16K
  • Abbott$6K
  • Biosense Webster, Inc.$6K
  • Medtronic$5K
  • Medical Device Business Services, Inc.$5K
  • Biotronik Inc.$3K
  • plus $1K from 7 others

What the payments were for

  • Consulting fees$9,37522%
  • Grants$19,49046%
  • Travel & lodging$6,37615%
  • Food & beverage$6,58316%
  • Education$2951%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,119 in reported general payments places this provider in the 65th percentile of 42 clinical cardiac electrophysiology providers in Alabama.

See all clinical cardiac electrophysiology providers in Alabama

Medicare billing

Part B allowed, 2024
$303,921
Medicare patients
2,031
Services billed
5,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban608$507,710
EntrestoSacubitril/Valsartan134$128,154
XareltoRivaroxaban88$79,939
Dofetilide35$8,081
Metoprolol Succinate281$3,692
Flecainide Acetate59$2,701
Carvedilol158$1,673
Dilt-XrDiltiazem Hcl63$1,667
Bisoprolol Fumarate58$1,520
Amiodarone Hcl74$1,427
Potassium Chloride71$1,242
SotalolSotalol Hcl45$1,084
Hydralazine Hcl42$817
Lisinopril110$695
Amlodipine Besylate118$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$507,710608 claims
Johnson & JohnsonXarelto$31$79,93988 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 42 clinical cardiac electrophysiology providers in Alabama.

Other clinical cardiac electrophysiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →